Delonix Bioworks is a Shanghai-based startup using synthetic biology to design bacteria to act as safer and more effective vaccines against bacterial infections and cancer.
The Delonix team has developed a novel approach that builds on the established concept of live attenuated bacteria and combines it with the latest developments in synthetic biology. Delonix’s synthetic biology and antigen discovery platforms enable rational design and programming of bacteria into vaccines that are expected to be safer and more effective.
Initial lead programs will target anti-microbial resistance (AMR), including resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA). The company says that antimicrobial resistance is projected to cause up to 10 million deaths annually by 2050.
The company recently raised $14m in seed funding to accelerate the building of its platforms and advance its pipelines of synthetic vaccines to clinical trials.
Subscribe for alerts on new companies featured on Startups.Bio
ImmuneID is a precision immunology company that has developed a genome-wide, high-throughput platform to provide an understanding of individual immune responses. ImmuneID's aiSPIRE platform screens billions of …